Department of Medicine, Intermountain Healthcare, Murray, UT.
Department of Medicine, Intermountain Healthcare, Murray, UT.
Chest. 2021 Dec;160(6):2247-2259. doi: 10.1016/j.chest.2021.07.056. Epub 2021 Aug 2.
This is the 2nd update to the 9th edition of these guidelines. We provide recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions, four of which have not been addressed previously.
We generate strong and weak recommendations based on high-, moderate-, and low-certainty evidence, using GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology.
The panel generated 29 guidance statements, 13 of which are graded as strong recommendations, covering aspects of antithrombotic management of VTE from initial management through secondary prevention and risk reduction of postthrombotic syndrome. Four new guidance statements have been added that did not appear in the 9th edition (2012) or 1st update (2016). Eight statements have been substantially modified from the 1st update.
New evidence has emerged since 2016 that further informs the standard of care for patients with VTE. Substantial uncertainty remains regarding important management questions, particularly in limited disease and special patient populations.
这是第 9 版指南的第 2 次更新。我们提供了 17 个 PICO(人群、干预、对照、结局)问题的建议,其中有 4 个问题以前没有涉及过。
我们使用 GRADE(推荐分级、评估、发展与评价)方法,根据高、中、低确定性证据生成强推荐和弱推荐。
专家组生成了 29 条指导意见,其中 13 条被评为强推荐,涵盖了从初始管理到二级预防和血栓后综合征风险降低的 VTE 抗栓管理的各个方面。新增了 4 条 9 版(2012 年)或 1 次更新(2016 年)中没有的新指导意见。8 条意见从 1 次更新中进行了实质性修改。
自 2016 年以来,出现了新的证据,进一步为 VTE 患者的治疗标准提供了信息。在重要的管理问题上仍然存在很大的不确定性,特别是在疾病有限和特殊患者群体中。